🟠 Moderate Evidence
Vitamin B12 deficiency does not simply reduce circulating B12 levels—it creates a metabolic trap that functionally depletes folate inside cells, preventing DNA synthesis even when dietary folate intake is adequate. According to research published in the British Journal of Haematology, this mechanism explains why B12-deficient patients develop megaloblastic anemia and other cellular division impairments despite normal folate stores.
Key takeaways
- B12 deficiency traps folate in its 5-methylTHF form, a metabolically inactive state that cells cannot use for DNA synthesis
- The methionine synthase enzyme, which requires methylcobalamin (B12), is the only mechanism to release trapped folate; without B12, this exit is sealed
- In a documented case study, 94.5% of red blood cell folate was trapped during B12 deficiency; this dropped to 67.4% after B12 repletion
- This mechanism represents “the first time that virtually all features of the methylfolate trap hypothesis have been demonstrated in a human,” according to Smulders et al. (British Journal of Haematology, 2006)
Study at a Glance
| Source | British Journal of Haematology |
| Study type | Case report with biochemical analysis |
| Population | B12-deficient patient with MTHFR C677T polymorphism |
| Key measurement | RBC folate speciation, homocysteine, DNA methylation |
| Year | 2006 |
Folate Compartmentalization During B12 Deficiency and Repletion
Percentage of RBC folate in 5-methylTHF form, before and after B12 supplementation
Source: Smulders et al., British Journal of Haematology, 2006 | Georgian Medical Journal News
The Biochemical Mechanism: A One-Way Metabolic Trap
Inside cells, folate cycles through multiple chemical forms—each serving different functions in nucleotide synthesis and methylation reactions. The critical enzyme MTHFR (methylenetetrahydrofolate reductase) catalyzes an essentially irreversible conversion: it transforms 5,10-methyleneTHF into 5-methylTHF. Once this conversion occurs, there is only one biochemical exit: the enzyme methionine synthase must strip the methyl group away, simultaneously converting homocysteine to methionine.
Methionine synthase requires methylcobalamin (the B12 form) as an essential cofactor. Without adequate B12, this enzyme becomes catalytically inactive. The result is biochemically straightforward: folate cannot escape from its 5-methylTHF form. Usable folate pools—particularly THF (tetrahydrofolate), which is required for DNA synthesis—become depleted, even though total folate stores may appear adequate on standard testing.
Clinical Evidence: Direct Demonstration in a Human Patient
Smulders et al., writing in the British Journal of Haematology (2006), documented this mechanism directly in a B12-deficient patient. During the deficiency state, 94.5% of red blood cell folate was sequestered in the 5-methylTHF form—biochemically trapped and inaccessible for DNA synthesis. After B12 supplementation restored methionine synthase activity, this proportion fell to 67.4%, releasing trapped folate back into usable forms.
The same patient showed a dramatic fall in global DNA methylation capacity during B12 deficiency: methylation was 22% lower compared to the post-repletion state. Plasma homocysteine, a marker of impaired methylation, stood at 52.9 μmol/L during deficiency—more than three times the post-repletion level of 16.8 μmol/L. The authors noted that this patient carried a homozygous MTHFR C677T polymorphism, which reduces MTHFR enzyme activity and may have amplified the trapping effect in this particular case.
“During B12 deficiency, 94.5% of RBC folate was trapped as 5-methylTHF. This is the first time that virtually all features of the methylfolate trap hypothesis have been demonstrated in a human.”
— Smulders et al., British Journal of Haematology (2006)
Why This Matters: Megaloblastic Anemia and Beyond
The consequence of folate trapping is impaired DNA replication. DNA synthesis depends critically on THF-derived thymidylate, which is required for nucleotide formation. Cells that divide rapidly—particularly red blood cell precursors in the bone marrow—cannot complete cell division when thymidylate becomes depleted. The result is megaloblastic anemia: abnormally enlarged immature red cells that fail to divide, leading to reduced oxygen-carrying capacity and systemic symptoms.
This mechanism also explains why standard folate supplementation alone may fail to resolve B12 deficiency symptoms. If B12 is genuinely deficient, administering more folate cannot unlock the trapped folate—methionine synthase remains inactive, the exit remains sealed, and cells cannot synthesize DNA. This is why clinicians must address B12 deficiency directly through B12 repletion, not simply by increasing folate intake. See our Clinical Updates section for more on B12 assessment and treatment protocols.
Implications for Diagnosis and Management
This mechanism has important diagnostic implications. A patient may present with macrocytic anemia (enlarged red cells) and adequate serum or red cell folate levels, yet still be folate-deficient at the functional level—because their folate is metabolically trapped. Standard folate assays measure total folate, not the proportion available for DNA synthesis. B12 level assessment, methylmalonic acid, homocysteine, and holotranscobalamin testing become critical diagnostic tools to identify B12 deficiency that is driving the folate trap.
Genetic factors may modulate the severity of folate trapping. As noted in the Smulders case, patients with reduced MTHFR activity (from polymorphisms like C677T) may experience more severe trapping effects, suggesting that personalized assessment of folate metabolism could inform treatment strategies. Research from Field et al. (Proceedings of the National Academy of Sciences, 2017) extends this understanding in population-level studies, though individual-level biochemical characterization remains the gold standard for diagnosis.
What this means
Frequently asked questions
Why doesn’t taking more folate fix B12 deficiency symptoms?
Because B12 deficiency traps folate in a form cells cannot use for DNA synthesis. The enzyme methionine synthase, which requires B12 as a cofactor, is the only mechanism that releases trapped folate. Without B12, more folate intake simply adds to the trapped pool. B12 repletion must come first to restore the enzyme’s activity and free trapped folate.
Can genetic variations affect how severe the folate trap becomes?
Yes. The patient described by Smulders et al. (2006) carried a homozygous MTHFR C677T polymorphism, which reduces the activity of the MTHFR enzyme that initiates folate methylation. This genetic variation may have amplified the trapping effect in that individual. Genetic variation in folate metabolism enzymes may influence individual susceptibility to functional folate deficiency during B12 shortage.
Should I get genetic testing for MTHFR before treating B12 deficiency?
Routine MTHFR testing is not currently recommended as standard clinical practice for B12 deficiency diagnosis or treatment. Standard B12 assessment (serum B12, methylmalonic acid, homocysteine) is sufficient to guide treatment. MTHFR polymorphism testing may be considered in complex or refractory cases, but it remains a research application rather than standard clinical care at this time.
The methylfolate trap demonstrates how tightly integrated micronutrient metabolism truly is: a deficiency in one nutrient (B12) directly impairs the utilization of another (folate), even when the second nutrient is present in adequate amounts. This underscores why comprehensive B12 and folate status assessment—beyond simple serum level testing—is essential for accurate diagnosis and effective treatment of nutritional deficiencies. For more evidence-based clinical information, visit the Pharmacy & Prescribing section on our news platform.
Source: Smulders et al., British Journal of Haematology (2006); Field et al., Proceedings of the National Academy of Sciences (2017)
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
